Home / Multi-site Clinical Trial Underway for ERX-963, Potential Therapy for Excessive Daytime Sleepiness in DM1

Multi-site Clinical Trial Underway for ERX-963, Potential Therapy for Excessive Daytime Sleepiness in DM1

New Clinical Trial Underway

A new clinical trial is underway to study the safety, tolerability and pharmacokinetics of ERX-963, a potential therapy for symptoms of excessive daytime sleepiness that may include impaired attention or concentration. The first site for that study, Stanford University, is now recruiting, under the direction of Principal Investigator Jacinda Sampson, MD, PhD. Below is a brief summary of the study. Additional details can be found on clinicaltrials.gov.

This research study is evaluating the safety and effectiveness of this investigational medicine compared to placebo (inactive medication) for symptoms of excessive daytime sleepiness that may include impaired attention or concentration.

Participant Qualifications

Individuals may be eligible if they:

  • Are 18-60 years of age
  • Have been diagnosed with Myotonic Dystrophy, Type 1 
  • Do not have significant respiratory disease, severe sleep apnea, liver disease, or history of seizures or panic disorder

Qualified participants will receive study-related medical exams and investigational medication at no cost.  Participants will be asked to come to the research center to complete 4 study visits (screening visit, treatment period 1 and 2, and a follow-up visit).

Financial Reimbursement Available

Financial reimbursement for travel and lodging costs will be provided to qualified participants and a caregiver traveling approximately more than 75 miles to Stanford.

Questions?

For more information, contact Mitchell Reddan, Stanford Neurosciences Health Center, at 650-725-4341 or by email at neuromuscularresearch@stanford.edu. Find more information online at clinicaltrials.gov.

 

 

 

Partners

© Myotonic Dystrophy Foundation. All rights reserved.